[Satisfaction of a pharmacovigilance declaration support network in general practice]

Damien Driot; Lucile Figuet; Jordan Birebent; Sandra Coste; Geneviève Durrieu; Julien Jacquot; Michel Bismuth

doi:10.1016/j.therap.2018.04.003

[Satisfaction of a pharmacovigilance declaration support network in general practice]

Therapie. 2018 Dec;73(6):483-493. doi: 10.1016/j.therap.2018.04.003. Epub 2018 Apr 28.

[Article in French]

Authors

Damien Driot¹, Lucile Figuet², Jordan Birebent², Sandra Coste², Geneviève Durrieu³, Julien Jacquot³, Michel Bismuth²

Affiliations

¹ Département universitaire de médecine générale, faculté de médecine de Toulouse, université Paul Sabatier, 133, route de Narbonne, 31062 Toulouse, France. Electronic address: [email protected].
² Département universitaire de médecine générale, faculté de médecine de Toulouse, université Paul Sabatier, 133, route de Narbonne, 31062 Toulouse, France.
³ Centre régional Midi-Pyrénées de pharmacovigilance, faculté de médecine de Toulouse, université Paul-Sabatier, 31000 Toulouse, France.

PMID: 29921459
DOI: 10.1016/j.therap.2018.04.003

Abstract

Objective: General practitioners (GPs) report little adverse drug reactions (ADR), although it is mandatory in France. The objective was to evaluate the satisfaction of the GPs who participated to a pharmacovigilance ADR declaration support network via a clinical research assistant (CRA) moving to their GP office in the French South-West region of Midi-Pyrénées.

Study design: A satisfaction questionnaire was sent to the 59 active GPs of this network in November 2016.

Results: A total number of 44 GPs responded to the survey (mean age 44±11years; 48% of women). The overall satisfaction grade was rated 9/10 (SD±1). The personalized help from a CRA was highly appreciated (n=39; 89%), reduced time-loss (n=35; 90%), and facilitated communication with the local pharmacovigilance department (n=33; 85%). Most GP (95%; n=35) stated that they would keep reporting ADRs, 83% (n=35) stated to declare ADRs via the CRA, the others stated to declare ADRs directly to the Regional Pharmacovigilance Center, mainly via numerical or online tools. For 59% (n=26) their participation to the network had a positive impact on their relationship with patients through the improvement of their vigilance to ADR.

Discussion: Most of the active GP answered. They were very satisfied of the pharmacovigilance CRA network helping ADR reports. It may corroborate the increase of ADRs reporting in Midi-Pyrénées since this network was set up.

Keywords: Adverse effects; Community networks; Effets indésirables; General practice; Médecine générale; Pharmacovigilance; Primary health care; Réseaux communautaires; Soins de santé primaires.

MeSH terms

Adult
Adverse Drug Reaction Reporting Systems* / organization & administration
Adverse Drug Reaction Reporting Systems* / standards
Community Networks* / organization & administration
Community Networks* / standards
Community Networks* / statistics & numerical data
Drug-Related Side Effects and Adverse Reactions / diagnosis
Drug-Related Side Effects and Adverse Reactions / epidemiology
Female
France / epidemiology
General Practice / methods
General Practice / organization & administration
General Practice / standards
General Practice / statistics & numerical data
General Practitioners* / psychology
General Practitioners* / statistics & numerical data
Humans
Male
Middle Aged
Personal Satisfaction*
Pharmacovigilance*
Primary Health Care / organization & administration
Primary Health Care / standards
Primary Health Care / statistics & numerical data
Surveys and Questionnaires